K36 Therapeutics

K36 Therapeutics is developing breakthrough epigenetic modulation therapies to treat multiple myeloma. Treatment options for multiple myeloma have improved in recent years, however, there are still many patients with high-risk mutations such as t(4;14) with poor prognosis and no effective treatment.This mutation leads to high expression of the MMSET gene. K36tx’s lead candidate, KTX-1001, is a selective inhibitor of the histone methyltransferase MMSET which is overexpressed in around 20% of multiple myeloma patients. K36tx is currently enrolling patients to begin KTX-1001 clinical testing.

Jobs: